RATIOPHARM ApS

APSDissolved

CVR 25762290Parallelvej 10, 2800 Kongens LyngbyWholesale of pharmaceutical and medical goods· NACE 4646Est. 2000 · 25 years old— employees

Overview

RATIOPHARM ApS is a Danish APS based in Kongens Lyngby, operating in the Wholesale of pharmaceutical and medical goods sector. Incorporated in 2000, the company reported a gross profit of DKK 328.5k in its latest annual filing.

Gross profit 2013

0.3M DKK

−28% vs 2012

EBITDA margin (of gross profit)

100.0 %

−28% vs 2012

Net profit 2013

0.1M DKK

-81% vs 2012

Key ratios

See full ratios →

87.7 %

Very strong

Among the 20% highest rated companies in the industry

20122013

7.6×

Very strong

Among the 10% highest rated companies in the industry

20122013

4.6 %

Average

Around the average of companies in the same industry

20122013

EBITDA — year on year

DKK thousands

Key figures

Annual report 2013

Gross profit	0.3M DKK	-28%
EBITDA	0.3M DKK	-28%
Net profit	0.1M DKK	-81%
Total assets	2.1M DKK	-88%
Equity	1.8M DKK	-89%
Employees	—	—

Financial development

In its most recent annual report (2013), RATIOPHARM ApS reported a gross profit of DKK 328.5k, a decrease of 28% on the year before. The figures on this page draw on 2 annual filings covering 2012 to 2013. The bottom line showed a net profit of DKK 95.6k, and the EBITDA margin stood at 100%.

At the end of 2013, equity financed 87.7% of the balance sheet, and current assets covered short-term debt 7.6 times.

Financials

Gross profit

DKK thousands

EBITDA

DKK thousands

Income statement

DKK thousands

Item	2013	2012
Gross profit	329	457
Staff expenses	-0	-1
EBITDA	329	456
Depreciation & amort.	-304	-304
EBIT	24	152
Net financials	55	-35
Profit before tax	79	117
Tax	-16	-397
Net profit	96	514

Get a credit rating – not just the numbers

Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.

See the credit rating

Balance sheet

DKK thousands

Item	2013	2012
Total assets	2,071	16,691
Equity	1,816	15,875
Long-term debt	0	0
Short-term debt	255	815
Total debt	255	815

Financial ratios

5-year trend

EBITDA margin (of gross profit)

100.0 %

20122013

Equity ratio

87.7 %

Very strong

Among the 20% highest rated companies in the industry

20122013

Return on equity

5.3 %

Weak

Among the 40% lowest rated companies in the industry

20122013

Net profit margin (of gross profit)

29.1 %

20122013

Asset turnover (of gross profit)

0.16×

20122013

Debt / equity

0.14×

Very strong

Among the 20% highest rated companies in the industry

20122013

Sector performance

23 of 28 ratios graded

28 financial ratios from the latest filing, each graded against companies in the same industry.

Profitability

Return on equity (ROE)Weak

Among the 40% lowest rated companies in the industry

Net profit as a percentage of equity — the return the owners earned on their invested capital this year.

Return on assets (ROA)Average

Around the average of companies in the same industry

Net profit as a percentage of total assets — the return generated on the capital employed.

Return on net assets (RONA)Average

Around the average of companies in the same industry

Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.

Basic earning power (BEP)Average

Around the average of companies in the same industry

EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.

Capacity ratioAverage

Around the average of companies in the same industry

Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.

Gross marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.

Operating marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.

Net profit marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

The profit for the year as a share of revenue — the company's ability to turn revenue into profit.

Liquidity

Current ratioVery strong

Among the 10% highest rated companies in the industry

Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.

Quick ratioVery strong

Among the 10% highest rated companies in the industry

Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.

Cash ratioAverage

Around the average of companies in the same industry

Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.

Current assets to equityStrong

Among the 30% highest rated companies in the industry

Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.

Fixed assets to long-term capitalAverage

Around the average of companies in the same industry

Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.

Cash conversion ratioVery strong

Among the 10% highest rated companies in the industry

Cash flow relative to profit — the ability to convert reported profits into accessible cash.

Debt & solvency

Solidity ratioVery strong

Among the 20% highest rated companies in the industry

Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.

Debt ratioVery strong

Among the 10% highest rated companies in the industry

Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.

Debt to equityVery strong

Among the 20% highest rated companies in the industry

Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.

Liabilities to equityVery strong

Among the 20% highest rated companies in the industry

Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.

Income to debtStrong

Among the 30% highest rated companies in the industry

Profit relative to debt — the ability to create earnings while operating with debt.

EBITDA to debtVery strong

Among the 10% highest rated companies in the industry

EBITDA relative to debt — how much operating earnings are available to service the debt.

Interest coverageStrong

Among the 30% highest rated companies in the industry

The ability to pay the interest on the company's debt out of its earnings.

Interest rate on debtStrong

Among the 30% highest rated companies in the industry

Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.

Interest marginAverage

Around the average of companies in the same industry

The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.

Efficiency & development

Equity to contributed capitalWeak

Among the 40% lowest rated companies in the industry

Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.

One-year change in equityVery weak

Among the 10% lowest rated companies in the industry

The size of this year's increase or decrease in the company's equity.

One-year change in debtVery strong

Among the 10% highest rated companies in the industry

The size of this year's increase or decrease in the company's debt.

Asset turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to total assets — the ability to generate revenue from the asset base.

Inventory turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.

Annual reports & filings

Annual report 2013
Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
View PDF
Annual report 2012
Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
View PDF

People & ownership

Management

Actively employed in the business

Name	Role	Member since

Former (12)


PM Peter Mikael Burestedt Management	Management	2012 – 2013
LJ Lone Juul Darket Management	Management	2010 – 2012
HB Hans Bruun Ringsing Management	Management	2001 – 2005
KV Kim Vallentin Peetz Management	Management	2012 – 2015
TO Tim Oreskovic Management	Management	2014 – 2015
EG Emile Gérardus Wilhelmus Hendr icus Loof Management	Management	2010 – 2012
JS Jarkko-Tapani Suokas Management	Management	2009 – 2010
GN Gertjan Noordermeer Management	Management	2014 – 2014
BL Betina Liliendal Management	Management	2013 – 2015
PA Peter Andreas Stakemann Management	Management	2000 – 2001
JE Jan Erik Anders Jungbeck Management	Management	2005 – 2009
TJ Theodorus Jacobus Andriessen Management	Management	2010 – 2014

Board of directors

Non-executive oversight

Name	Role	Member since

Former (13)


MJ Markus Joachim Schürholz Chairman	Chairman	2001 – 2004
AH Annemette Heller Board of Directors	Board of Directors	2000 – 2001
PT Pekka Tapani Mäkelä Board of Directors	Board of Directors	2001 – 2001
WG Werner Gerd Lehmann Chairman	Chairman	2005 – 2010
JV Janos Vaczi Board of Directors	Board of Directors	2002 – 2005
HB Hans Bruun Ringsing Board of Directors	Board of Directors	2004 – 2005
FR Frank Rainer Breuing Board of Directors	Board of Directors	2005 – 2009
AS Andrej Salat Board of Directors	Board of Directors	2009 – 2010
JS Jarkko-Tapani Suokas Board of Directors	Board of Directors	2009 – 2010
PA Peter Andreas Stakemann Board of Directors	Board of Directors	2000 – 2001
JE Jan Erik Anders Jungbeck Board of Directors	Board of Directors	2005 – 2009
KM Kim Madsen Chairman	Chairman	2000 – 2001
FB Frank Breuing Board of Directors	Board of Directors	2001 – 2001

Shareholders

Active legal owners

No shareholder data available.

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.

One in three Danish companies experiences fraud

Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.

See the fraud module

Related companies

Company hierarchy

No registered parent or subsidiaries

Board network connections

Board members of RATIOPHARM ApS also hold positions in 27 other companies.

Person	Role here	Other companies
Kim Madsen	Chairman	12 companiesMany roles
Peter Andreas Stakemann	Management	9 companiesMany roles
Lone Juul Darket	Management	2 companies
Hans Bruun Ringsing	Management	2 companies
Kim Vallentin Peetz	Management	1 company
Betina Liliendal	Management	1 company

Frequently asked questions

What is the CVR number of RATIOPHARM ApS?

RATIOPHARM ApS is registered with CVR / Virk under CVR 25762290.

What is the gross profit of RATIOPHARM ApS?

RATIOPHARM ApS reported a gross profit of DKK 328.5k in 2013.

Where is RATIOPHARM ApS headquartered?

RATIOPHARM ApS's registered address is Parallelvej 10.